Adynxx Inc. announced the completion of enrollment in the Phase 1 clinical study in healthy volunteers of its lead investigational drug candidate for the prevention of acute and chronic post-surgical pain, AYX1. The Adynxx therapeutic platform -- a novel approach to treating and preventing pain -- has the potential to transform pain management. "The clinical development of this breakthrough technology is being driven by an accomplished management team that has a track record of success that includes building successful biotech companies and attaining multiple new drug approvals.

The Adynxx team is well positioned to achieve goal of developing these new treatment options for preventing pain. The 30 subject, dose-escalating study is currently evaluating AYX1 in five cohorts of healthy volunteers. Later this year, Adynxx plans to move into a proof-of-concept Phase 2 clinical study assessing the ability of a single administration of AYX1 at the time of surgery to reduce acute pain, prevent the transition to persistent post-surgical pain and consequently improve functional recovery.